Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
symbols : NVAX save search
Novavax Reports First Quarter 2023 Financial Results and Operational Highlights
Published: 2023-05-09 (Crawled : 12:00) - biospace.com/
NVAX | $4.285 5.28% 1.6M
|
Health Technology
|
| O: 20.4%
H: 26.64%
C: 6.13%
financial results
Positive Phase 2 Topline Results Show Novavax's COVID-Influenza Combination, Stand-alone Influenza and High-dose COVID Vaccine Candidates Demonstrate Robust Immune Responses
Published: 2023-05-09 (Crawled : 12:00) - biospace.com/
SNY | News | $47.5 0.74% 450K
|
Health Technology
|
| O: -0.58%
H: 0.0%
C: 0.0%
NVAX | $4.285 5.28% 1.6M
|
Health Technology
|
| O: 20.4%
H: 26.64%
C: 6.13%
covid vaccine positive influenza topline results show
Novavax COVID-19 Vaccine Demonstrates 89.3% Efficacy in UK Phase 3 Trial
Published: 2021-01-28 (Crawled : 22:01) - globenewswire.com
NVAX | $4.285 5.28% 1.6M
|
Health Technology
|
| O: 42.56%
H: 23.27%
C: 15.65%
covid vaccine phase 3 trial covid-19
Novavax and Gavi Reach Settlement on 2021 COVID-19 Vaccine Advance Purchase Agreement
Published: 2024-02-22 (Crawled : 11:00) - prnewswire.com
NVAX | $4.285 5.28% 1.6M
|
Health Technology
|
| O: 12.06%
H: 22.42%
C: 9.42%
covid-19 vaccine reach agreement
Novavax to Host Conference Call to Discuss First Quarter 2022 Financial Results and Operational Highlights on May 9, 2022
Published: 2022-05-02 (Crawled : 21:00) - biospace.com/
NVAX | $4.285 5.28% 1.6M
|
Health Technology
|
| O: -0.38%
H: 19.8%
C: 19.71%
conference results
Novavax Announces Pricing of $150 Million Offering of Convertible Senior Notes
Published: 2022-12-16 (Crawled : 05:00) - prnewswire.com
NVAX | $4.285 5.28% 1.6M
|
Health Technology
|
| O: -15.37%
H: 16.49%
C: 15.14%
offering
Novavax Announces Pricing of $65 Million Public Offering of Common Stock
Published: 2022-12-16 (Crawled : 05:00) - prnewswire.com
NVAX | $4.285 5.28% 1.6M
|
Health Technology
|
| O: -15.37%
H: 16.49%
C: 15.14%
offering
Novavax Announces Pricing of $65 Million Public Offering of Common Stock - December 16, 2022
Published: 2022-12-16 (Crawled : 07:00) - biospace.com/
NVAX | $4.285 5.28% 1.6M
|
Health Technology
|
| O: -15.37%
H: 16.49%
C: 15.14%
offering
Novavax Announces Pricing of $65 Million Public Offering of Common Stock - December 16, 2022 Novavax, Inc. announced the pricing of an underwritten public offering to sell 6,500,000 shares of its commo...
Published: 2022-12-16 (Crawled : 08:00) - biospace.com/
NVAX | $4.285 5.28% 1.6M
|
Health Technology
|
| O: -15.37%
H: 16.49%
C: 15.14%
offering
Novavax's Updated Protein-based XBB COVID Vaccine Induced Neutralizing Responses Against Emerging Subvariants, Including EG.5.1 and XBB.1.16.6
Published: 2023-08-22 (Crawled : 11:00) - prnewswire.com
NVAX | $4.285 5.28% 1.6M
|
Health Technology
|
| O: 2.85%
H: 15.66%
C: 10.36%
covid vaccine
Novavax Announces Closing of $175.25 Million Offering of Convertible Senior Notes Due 2027 and $74.75 Million Public Offering of Common Stock
Published: 2022-12-28 (Crawled : 23:00) - prnewswire.com
NVAX | $4.285 5.28% 1.6M
|
Health Technology
|
| O: 0.66%
H: 15.6%
C: 6.58%
offering
Novavax and Serum Institute of India Receive Emergency Use Authorization for COVID-19 Vaccine in India
Published: 2021-12-28 (Crawled : 15:30) - biospace.com/
NVAX | $4.285 5.28% 1.6M
|
Health Technology
|
| O: -2.94%
H: 14.91%
C: 1.75%
covid-19 covid authorization india vaccine merge emergency use authorization
FDA Announces Vaccines and Related Biological Products Advisory Committee Review of Novavax' COVID-19 Vaccine
Published: 2022-04-29 (Crawled : 19:00) - biospace.com/
NVAX | $4.285 5.28% 1.6M
|
Health Technology
|
| O: 3.79%
H: 14.21%
C: -1.92%
covid-19 fda vaccine review
Novavax Nuvaxovid™ COVID-19 Vaccine Conditionally Authorized in the European Union for Adolescents Aged 12 Through 17
Published: 2022-07-05 (Crawled : 14:00) - prnewswire.com
NVAX | $4.285 5.28% 1.6M
|
Health Technology
|
| O: -0.68%
H: 13.79%
C: 13.27%
covid-19 authorized vaccine
Novavax COVID-19-Influenza Combination Vaccine Candidate Induced Antibody and T-Cell Responses Against SARS-CoV-2 and Homologous and Heterologous Influenza Strains
Published: 2022-10-13 (Crawled : 13:00) - prnewswire.com
NVAX | $4.285 5.28% 1.6M
|
Health Technology
|
| O: -5.01%
H: 13.34%
C: 10.69%
covid-19 candidate antibody vaccine t-cell sars-cov-2 influenza
Novavax Announces Expanded Agreement with SK bioscience to Manufacture COVID-19 Vaccine Containing Omicron Variant and Manufacture the Novavax COVID-19 Vaccine in Prefilled Syringes
Published: 2022-07-19 (Crawled : 13:00) - biospace.com/
NVAX | $4.285 5.28% 1.6M
|
Health Technology
|
| O: 1.44%
H: 13.25%
C: 10.02%
covid-19 vaccine agreement bioscience
Novavax and European Commission Finalize Advance Purchase Agreement for up to 200 million doses of COVID-19 Vaccine
Published: 2021-08-04 (Crawled : 14:00) - biospace.com/
NVAX | $4.285 5.28% 1.6M
|
Health Technology
|
| O: 9.33%
H: 12.16%
C: 8.56%
covid europe vaccine
Novavax Nuvaxovid™ COVID-19 Vaccine▼ Authorized in the United Kingdom for Use as a Booster in Adults
Published: 2022-11-09 (Crawled : 15:20) - biospace.com/
NVAX | $4.285 5.28% 1.6M
|
Health Technology
|
| O: 0.15%
H: 11.69%
C: -5.34%
covid-19 authorized
U.S. CDC Advisory Committee Unanimously Recommends Novavax COVID-19 Vaccine, Adjuvanted as a Primary Series for Individuals Aged 18 and Older
Published: 2022-07-19 (Crawled : 21:00) - prnewswire.com
NVAX | $4.285 5.28% 1.6M
|
Health Technology
|
| O: -0.16%
H: 11.38%
C: 2.87%
covid-19
Novavax to Participate in Fireside Chat at the 2021 Cantor Virtual Global Healthcare Conference
Published: 2021-09-23 (Crawled : 13:15) - prnewswire.com
NVAX | $4.285 5.28% 1.6M
|
Health Technology
|
| O: 0.96%
H: 11.29%
C: 9.85%
conference
Gainers vs Losers
| 87% | 13% |
Top 10 Gainers
MTTR | News M | $4.595 164.08% 13M
|
AGBA | $2.61 108.8% 41M
|
Finance
CZOO | $9.32 86.77% 18M
|
EDBL | News | $6.75 79.52% 1.5M
|
MTC | $2.28 46.15% 2.6M
|
Technology Services
OPRT | News | $3.14 39.56% 7.6M
|
Finance
VNRX | $0.8 33.33% 2.9M
|
Health Technology
MLEC | $1.865 33.21% 2.4M
|
n/a
PALI | $6.37 29.21% 21M
|
Manufacturing
LOCL | $3.33 27.59% 43K
|
Your saved searches
Save your searches and get alerts when important news are released.